REYON Pharmaceutical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
August 16, 2022 at 04:42 am EDT
Share
REYON Pharmaceutical Co., Ltd. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was KRW 0.00041 million compared to KRW 0.00031 million a year ago. Net loss was KRW 413.34 million compared to net income of KRW 3,046.71 million a year ago. Basic loss per share from continuing operations was KRW 25 compared to basic earnings per share from continuing operations of KRW 172 a year ago. Basic loss per share was KRW 25 compared to basic earnings per share of KRW 172 a year ago.
For the six months, negative sales was KRW 0.00032 million compared to sales of KRW 0.00033 million a year ago. Net income was KRW 1,481.11 million compared to KRW 4,057.15 million a year ago. Basic earnings per share from continuing operations was KRW 80 compared to KRW 229 a year ago. Basic earnings per share was KRW 80 compared to KRW 229 a year ago.
REYON PHARMACEUTICAL Co. Ltd. is a Korea-based company engaged in the provision of pharmaceutical products. The Companyâs products consist of remedies for circulatory systems, endocrine systems, digestive systems, respiratory systems, urinary systems and nervous systems, as well as eye drops, antibiotics, fever reducers, painkillers, anti-inflammatory drugs, antihistaminic agents, enzyme preparations, arthritis remedies, antitumor drugs and topical anesthetics, among others. It also produces pharmaceutical raw materials, such as arbekacin sulfate, alibendol, carvedilol, enocitabine, gemcitabine, glimepiride, lamotrigine, meloxicam, oxaliplatin, pioglitazone hydrochloride, ramipril, streptokinase, tacrolimus, thioctic acid, teicoplanin, voglibose and others.
REYON PHARMACEUTICAL CO., LTD. 
